Fierce Pharma
DECEMBER 14, 2022
Court swats down Vanda's patent suit against Teva and Apotex, clearing the way for Hetlioz generics. kdunleavy. Wed, 12/14/2022 - 13:54.
MedCity News
DECEMBER 14, 2022
To effectively reduce disparities and improve the quality and coordination of care, government, providers, and healthcare organizations are beginning to collaborate on how to best address the factors driving gaps between populations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
DECEMBER 14, 2022
Senators blast Pfizer's proposed COVID vaccine price hike as 'profiteering'. fkansteiner. Wed, 12/14/2022 - 09:00.
MedCity News
DECEMBER 14, 2022
Prevention is critical, and the ideas put forth in the White House’s proposal will likely help many Americans—particularly children—avoid weight gain as well as the downstream effects of obesity and its comorbidities. But more than 42% of U.S. adults already have obesity, and they need help now.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Fierce Pharma
DECEMBER 14, 2022
Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M. zbecker. Wed, 12/14/2022 - 11:22.
MedCity News
DECEMBER 14, 2022
Brightside Health has launched a new program called Crisis Care, specifically designed for individuals with elevated suicide risk. It is initially rolling out in 27 states, with plans to expand across the nation.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
DECEMBER 14, 2022
Moderna, Inc. and Merck have announced that a Phase IIb trial ( NCT03897881 ) of a personalised mRNA cancer vaccine (mRNA-4157/V940), in combination with KEYTRUDA ® , Merck’s anti-PD-1 therapy, demonstrated the first randomised evidence that a personalised neoantigen approach may be beneficial in treating melanoma. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA ® reduced the risk of recurrence or death by 44 percent (HR=0.56 [95 percent CI, 0.31-1.08]; one-sided p-valu
PharmExec
DECEMBER 14, 2022
Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.
MedCity News
DECEMBER 14, 2022
Wearables company Movano Health recently partnered with Novant Health to beta test its smart ring — which is designed for women — with the health system’s employees. The program is expected to prepare Movano for its first direct-to-consumer product launch in the first half of next year.
pharmaphorum
DECEMBER 14, 2022
The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna. The two partners have revealed the first clinical data from a phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – that are thought to be driving a patient’s cancer.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
DECEMBER 14, 2022
While most targeted protein degradation drug research has focused on cancer, Kymera Therapeutics’ Phase 1 data bring validation for this approach in treating inflammation. Kymera partner Sanofi has elected to advance the biotech’s program to mid-stage testing in two inflammatory skin disorders.
pharmaphorum
DECEMBER 14, 2022
Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. Read on for the hires headlines. New CEO joins UBC. Pharma consultancy United BioSource, or UBC (not to be confused with pharma company UCB), has promoted former chief operating officer Bekki Brown to the role of president and CEO, effective January 1.
MedCity News
DECEMBER 14, 2022
Here are four must-know key performance indicators that providers should know and use when looking to improve outcomes and the patient experience.
pharmaphorum
DECEMBER 14, 2022
Two virtual reality startups operating in the health category – BehaVR and OxfordVR – have agreed to pool their efforts on the development of digital therapeutics (DTx) for mental illnesses via a merger. The combined company will operate under the BehaVR brand, and starts operations with a $13 million cash injection from a Series B financing led by Oxford Science Enterprises and Optum Ventures with participation from Confluent Health, Accenture Ventures, Chrysalis Ventures, and Thornton Capital.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
European Pharmaceutical Review
DECEMBER 14, 2022
Two biopharmaceutical companies, UCB and Praxis Precision Medicines Inc., have announced their collaboration to advance potential therapeutics of KCNT1 related epilepsies, based on Praxis’ PRAX-020 small molecule programme, enabling Praxis to be potentially eligible to around $100 million in development milestones and related payments. Under the collaboration agreement, UCB will retain an exclusive option to in-license global development and commercialisation rights to any resulting KCNT1 small
PM360
DECEMBER 14, 2022
Perhaps no one can perfectly predict the future—or anticipate a global pandemic that is still having reverberations on our economy, our health, and the life sciences industry to this day—but. that didn’t stop us from asking 10 industry experts to take their best shot at anticipating what to expect in 2023 and beyond. After all, they can still read the tea leaves and provide their best interpretation of what is trending, where the industry is most struggling, and what might be coming down the pik
pharmaphorum
DECEMBER 14, 2022
People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive daytime sleepiness and can be treated with a stimulant like Provigil, Adderall, or Dexedrine in order to get people through their day. In addition to excessive daytime sleepiness, up to 60% of narcolepsy cases include cataplexy, which is a sudden loss of muscle control.
European Pharmaceutical Review
DECEMBER 14, 2022
For $4 billion , Takeda will acquire Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus Therapeutics and Nimbus Therapeutics’ tyrosine kinase 2 (TYK2) inhibitor NDI-034858, an oral, potential best-in-class selective allosteric TYK2 inhibitor for multiple autoimmune diseases following successful recent Phase IIb results in psoriasis. Under the terms of the agreement, Takeda will pay Nimbus Therapeutics $4 billion upfront, and up to $2 billion in sales-based milestone payments.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharma Pathway
DECEMBER 14, 2022
Torrent Pharmaceuticals- Openings for Parenteral Manufacturing (Insulin)/ Tablet Manufacturing- Apply Now. Job Description. We are looking for Technician Assistant/ Executive in Parenteral Manufacturing (Insulin)/ Tablet Manufacturing Department @ Torrent Pharmaceuticals Limited, Indrad (Ahmedabad), Plant. Department: Parenteral Manufacturing (Insulin).
Pharmaceutical Technology
DECEMBER 14, 2022
GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics. The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes.
Pharma Pathway
DECEMBER 14, 2022
Medopharm Pvt. Ltd-Walk-In Interview for Manufacturing/ Quality Assurance On 17th Dec’ 2022. Job Description. Walk-In Interview for Manufacturing/ Quality Assurance On 17th Dec’ 2022 @ Medopharm Pvt. Ltd. Departments: Manufacturing/ Quality Assurance. Qualification: M.Pharm/ B.Pharm. Experience : Freshers Or 0 to 2. Position: Trainee Officer. Location: Guduvanchery.
PharmaTech
DECEMBER 14, 2022
Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
PharmaTimes
DECEMBER 14, 2022
R&D partnership will identify and develop novel therapeutic targets for future therapies
Pharmaceutical Technology
DECEMBER 14, 2022
Harrow has signed a binding agreement to acquire exclusive US commercial rights to five ophthalmic products of Novartis. These products, namely, Ilevro, Vigamox, Maxidex, Nevanac and Triesence, have received approval from the Food and Drug Administration (FDA). According to the deal, Novartis will receive a one-time payment of $130m from Harrow at closing.
PM360
DECEMBER 14, 2022
The healthcare industry has experienced significant changes, which have been accelerated by the COVID-19 pandemic. Just some of the wide-ranging shifts include growing disease burden, evolving health needs, increasing consumer expectations, and higher expectations for affordable care. Now a series of macro environment headwinds such as inflation, rising interest rates, and the threat of economic contraction will further test the mettle and business acumen for all players in healthcare—especially
InCrowd
DECEMBER 14, 2022
What is your role within InCrowd? I’m the Chief Marketing Officer for Apollo, overseeing Apollo, InCrowd, and SHG B2B marketing. My responsibility—and that of my team—is to elevate Apollo, InCrowd, and SHG’s brands in the market, while ensuring a consistent message and market presence for each brand. My team and I highlight customer value, drive lead generation, support sales, and stimulate client utilization of both commercial solutions, as well as demonstrate InCrowd and SHG’s combined value t
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
DECEMBER 14, 2022
Takeda has entered an agreement for the acquisition of Nimbus Therapeutics’ allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858. An oral therapy, NDI-034858 is being analysed to treat various autoimmune ailments. According to the deal, Nimbus will receive $4bn in upfront payment from Takeda, which will also make two milestone payments worth $1bn each upon meeting annual net sales of $4bn and $5bn.
PharmaTimes
DECEMBER 14, 2022
The partnership combines systems in order to identify subtle phenotypic changes in living cells
Pharma Pathway
DECEMBER 14, 2022
Bharat Parenterals Limited-Walk-In Interviews for Freshers & Experienced in Production / QC On 15th Dec’ 2022. Job Description. Bharat Parenterals Limited is a Gujarat based pharmaceutical Company , established in 1992 by Mr. Ramesh Desai, who started the Company with a vision of making world class affordable medicines in Gujarat. Walk-In Interviews for Experienced Operators in Production @ Bharat Parenterals Limited.
PharmExec
DECEMBER 14, 2022
In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. While these third-party relationships can be full of risk and regulatory challenges, the right tech can help you navigate the complexities of compliance.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
275 
Let's personalize your content